2024-02-29T15:41:54-05:00 2023-05-31 870516083 LARSON & COMPANY PC 11240 S RIVER HEIGHTS DR SUITE 300 SOUTH JORDAN UT 840955123 990 2022-06-01 880189404 NEVADA CANCER RESEARCH FOUNDATION INC NEVA 7023840013 1750 E DESERT INN ROAD STE 200 LAS VEGAS NV 89169 SHANNON YULE PROGRAM COORDINATOR 7023840013 2024-02-15 true SHANNON YULE 999009999 false RICHARD SCORESBY CPA P00573067 8013131900 2024-02-15 2022 2023-04-26 12:10:37Z SHANNON YULE 1750 E DESERT INN ROAD STE 200 LAS VEGAS NV 89169 2425780 false X SNCRF.ORG X 1983 NV CANCER RESEARCH. 3 2 34 2 0 2412271 1934913 485198 5669 0 2412271 2425780 0 0 1412992 1686509 0 0 682685 823686 2095677 2510195 316594 -84415 637661 1774824 65633 762118 572028 1012706 CANCER RESEARCH. false false 1553579 41632 COOPERATIVE GROUP ONCOLOGY TRIALS: PATIENTS WERE TREATED IN VARIOUS RESEARCH PROGRAMS. IN TOTAL, FOLLOW-UP AND DATA SUBMISSIONS WERE DONE FOR 584 PATIENTS. 443632 443566 INDUSTRY SPONSOR TRIALS: 15 PATIENTS WERE TREATED USING VARIOUS CANCER- RELATED PHARMACEUTICALS. 1997211 true true false false false false false false false false true false false true true true true false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false true 3 0 true 34 true false false false false false false false false false false false false X 3 2 false false false false false false false true true false false true true true true true true true false false X SHANNON YULE 7023840013 1750 E DESERT INN ROAD STE 200 LAS VEGAS NV 89169 SHANNON YULE PROGRAM COOR 40.00 X 93792 0 13684 JOHN ELLERTON MD PRESIDENT/TR 3.00 X 30000 0 0 BRUCE BORGELT MD DIRECTOR 1.00 X 0 0 0 JIM CHRISTENSON MD SECRETARY 0.00 X X 0 0 0 123792 13684 false false false 1920000 14913 1934913 PHARMACEUTICAL TRIALS 541700 443566 443566 CANCER RESEARCH TRIALS 541700 41632 41632 485198 5669 5669 2425780 485198 5669 139845 114290 25555 1166165 947312 218853 256552 222256 34296 123947 100686 23261 17701 10781 6920 233042 203504 29538 1068 941 127 67400 41871 25529 84659 62003 22656 35881 10274 25607 4956 4956 32392 32392 3682 2173 1509 LAB FEES & PATIENT COSTS 238899 238899 BAD DEBT EXPENSE 46028 46028 PROGRAM SUPPLIES 41141 29147 11994 EQUIPMENT RENTAL & LEASE 9645 7359 2286 7192 5715 1477 2510195 1997211 512984 0 479288 167168 240114 657246 22118 228892 181468 89665 47424 68708 55671 585083 637661 1774824 162470 65633 599648 65633 762118 X 572028 1012706 572028 1012706 637661 1774824 X -84415 525093 X X false true true true true X 1093628 1102185 1769205 2412271 1934913 8312202 1093628 1102185 1769205 2412271 1934913 8312202 8312202 1442 993 1346 5669 9450 8321652 938339 0.99890 0.99820 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 39111 10725 28386 189781 170743 19038 47424 ROU ASSETS 585083 585083 LEASE LIABILITY 599648 599648 X 2604252 224500 224500 2379752 46028 46028 2425780 2688667 224500 224500 2464167 46028 46028 2510195 SCHEDULE D, PAGE 3, PART X BECAUSE THERE ARE NO KNOWN CIRCUMSTANCES THAT WOULD PLACE THE FOUNDATIONS STATUS AS A TAX-EXEMPT ORGANIZATION IN JEOPARDY, AND BECAUSE THE FOUNDATION DOES NOT ENGAGE IN UNRELATED BUSINESS INCOME ACTIVITIES, AND THERE ARE NO KNOWN UNCERTAIN TAX POSITIONS TAKEN OR TO BE TAKEN, NO PROVISION HAS BEEN MADE FOR INCOME TAXES. IN THE UNLIKELY EVENT ANY INCOME TAXES OR TAX- RELATED PENALTIES AND INTEREST ARE ASSESSED, SUCH ITEMS WOULD BE RECORDED AS GENERAL AND ADMINISTRATION EXPENSES. THE FOUNDATIONS RETURNS OF ORGANIZATION EXEMPT FROM INCOME TAX (FORM 990) GENERALLY REMAIN SUBJECT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE FOR THREE YEARS AFTER THEY ARE FILED. SCHEDULE D, PAGE 4, PART XI, LINE 4B BAD DEBT EXPENSE 46,028 SCHEDULE D, PAGE 4, PART XII, LINE 4B BAD DEBT EXPENSE 46,028 FORM 990, PAGE 6, PART VI, LINE 11B THE PROGRAM ADMINISTRATOR, PROGRAM COORDINATOR, AND THE PRINCIPAL INVESTIGATOR WILL REVIEW FORM 990 AND DISCUSS WITH EACH OTHER ANY QUESTIONS AND/OR COMMENTS. THE PROGRAM ADMINISTRATOR WILL DIRECT THESE QUESTIONS TO THE TAX PREPARER AND RELAY THE ANSWERS TO THE PROGRAM COORDINATOR AND PRINCIPAL INVESTIGATOR. IF THEY ARE SATISFIED WITH THE RESPONSES, NO FURTHER ACTION WILL BE REQUIRED. IF THEY ARE NOT SATISFIED, THEN A MEETING WILL BE SCHEDULED TO DISCUSS THE OUTSTANDING QUESTIONS WITH THE TAX RETURN PREPARER. FORM 990, PAGE 6, PART VI, LINE 12C ALL INVESTIGATORS WHO PARTICIPATE IN CLINICAL TRIALS ARE REQUIRED TO COMPLETE A FORM FDA 1572 ANNUALLY AND SUBMIT IT TO THE FOOD & DRUG ADMINISTRATION (FDA). THE FORM FDA 1572 IS A STATEMENT OF INVESTIGATOR (TITLE 21, CODE OF FEDERAL REGULATIONS (CFR) PART 312). IT INCLUDES A SUBPART, FINANCIAL DISCLOSURE FORM, WHICH THE INVESTIGATOR MUST ALSO COMPLETE ANNUALLY. IN ADDITION TO COMPLETING THE FORM FDA 1572, INVESTIGATOR AND FOUNDATION STAFF MUST ALSO COMPLETE AN ANNUAL FINANCIAL CONFLICT OF INTEREST DISCLOSURE FORM. THE POLICY AND PROCEDURES FOLLOWED BY THE FOUNDATION ARE INTENDED TO MEET THE MOST RECENT REQUIREMENTS PUBLISHED BY THE FEDERAL GOVERNMENT REGARDING REVISED FINANCIAL CONFLICT OF INTEREST (FCOI) REGULATION, PROMOTING OBJECTIVITY IN RESEARCH ON AUGUST 25, 2011 (42 CFR PART 50 SUBPART F AND 45 CFT PART 94). THE FOUNDATION WILL REPORT SIGNIFICANT FINANCIAL CONFLICTS OF INTEREST AS OUTLINED IN THE FEDERAL REGULATIONS. FORM 990, PAGE 6, PART VI, LINE 15A THE FOUNDATION USES DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS AT SIMILAR ORGANIZATIONS. FOUNDATION EMPLOYEES ARE EVALUATED ANNUALLY AND THE RATE OF PAY IS DISCUSSED DURING THE EVALUATION AND IS WRITTEN AS PART OF THE EVALUATION PROCESS. THESE ARE THE RECORDS WITH RESPECT TO THE DECISIONS REGARDING THE COMPENSATION PROCESS. THE PRINCIPAL INVESTIGATOR IS COMPENSATED PER FEDERAL GUIDELINES. NONE OF THE OTHER TRUSTEES RECEIVE COMPENSATION. FORM 990, PAGE 6, PART VI, LINE 19 IF A REQUEST IS MADE, THE PROGRAM ADMINISTRATOR, AFTER CONSULTATION WITH THE PRINCIPAL INVESTIGATOR, RESPONDS. FORM 990, PART XI, LINE 9 BAD DEBT EXPENSE -46,028 BAD DEBT EXPENSE 46,028 FORM 990, PAGE 12, PART XII, LINE 1 THE ORGANIZATION PREVIOUSLY USED THE CASH METHOD OF ACCOUNTING TO REPORT REVENUE AND FUNCTIONAL EXPENSES. BEGINNING WITH THE FILING OF THE 2022 FORM 990, THE ORGANIZATION WILL USE THE ACCRUAL METHOD OF ACCOUNTING TO REPORT RELATED REVENUE AND FUNCTIONAL EXPENSES. BECAUSE THE ORGANIZATION HAS NOT HAD TAXABLE INCOME REPORTED ON FORM 990-T IN THE PAST, THE ORGANIZATION BELIEVES IT IS EXEMPT FROM THE REQUIREMENT TO FILE FORM 3115 - APPLICATION FOR CHANGE IN ACCOUNTING METHOD IN ORDER TO RECEIVE APPROVAL FOR ABOVE MENTIONED CHANGE IN ACCOUNTING METHOD.